The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer

Received any systemic anticancer therapy, including surgery, local radiotherapy, cytotoxic drug therapy, targeted drug therapy, and experimental therapy;

Patients with other malignancies within five years prior to the start of the trial;

Combined with unstable systemic diseases, such as uncontrolled hypertension, severe arrhythmia, etc;

With active, known or suspected autoimmune disease, or autoimmune paraneoplastic syndrome requiring systemic therapy;